Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry.

Hsu VM, Chung L, Hummers LK, Shah A, Simms R, Bolster M, Hant FN, Silver RM, Fischer A, Hinchcliff ME, Varga J, Goldberg AZ, Derk CT, Schiopu E, Khanna D, Shapiro LS, Domsic RT, Medsger T, Mayes MD, Furst D, Csuka ME, Molitor JA, Saketkoo LA, Salazar CR, Steen VD.

J Rheumatol. 2019 Feb;46(2):176-183. doi: 10.3899/jrheum.180018. Epub 2018 Oct 1.

PMID:
30275260
2.

Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations.

Gorlova OY, Li Y, Gorlov I, Ying J, Chen WV, Assassi S, Reveille JD, Arnett FC, Zhou X, Bossini-Castillo L, Lopez-Isac E, Acosta-Herrera M, Gregersen PK, Lee AT, Steen VD, Fessler BJ, Khanna D, Schiopu E, Silver RM, Molitor JA, Furst DE, Kafaja S, Simms RW, Lafyatis RA, Carreira P, Simeon CP, Castellvi I, Beltran E, Ortego N, Amos CI, Martin J, Mayes MD.

PLoS One. 2018 Jan 2;13(1):e0189498. doi: 10.1371/journal.pone.0189498. eCollection 2018.

3.

A Great Gift.

Molitor JA.

Ann Intern Med. 2017 Sep 19;167(6):444. doi: 10.7326/M16-2739. No abstract available.

PMID:
28975330
4.

Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry.

Chung L, Fairchild RM, Furst DE, Li S, Alkassab F, Bolster MB, Csuka ME, Derk CT, Domsic RT, Fischer A, Frech TM, Gomberg-Maitland M, Gordon JK, Hinchcliff M, Hsu V, Hummers LK, Khanna D, Medsger TAJ, Molitor JA, Preston IR, Schiopu E, Shapiro L, Hant F, Silver R, Simms R, Varga J, Steen VD, Zamanian RT.

Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):106-113. Epub 2016 Nov 10.

PMID:
27908301
5.

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.

Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM; Sclerodema Lung Study II Investigators.

Lancet Respir Med. 2016 Sep;4(9):708-719. doi: 10.1016/S2213-2600(16)30152-7. Epub 2016 Jul 25.

6.

Correction: CD4+ Group 1 Innate Lymphoid Cells (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic Sclerosis.

Roan F, Stoklasek TA, Whalen E, Molitor JA, Bluestone JA, Buckner JH, Ziegler SF.

J Immunol. 2016 May 1;196(9):3966. doi: 10.4049/jimmunol.1600364. No abstract available.

7.

Association Between Serum Antibodies to Periodontal Bacteria and Rheumatoid Factor in the Third National Health and Nutrition Examination Survey.

Goh CE, Kopp J, Papapanou PN, Molitor JA, Demmer RT.

Arthritis Rheumatol. 2016 Oct;68(10):2384-93. doi: 10.1002/art.39724.

8.

CD4+ Group 1 Innate Lymphoid Cells (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic Sclerosis.

Roan F, Stoklasek TA, Whalen E, Molitor JA, Bluestone JA, Buckner JH, Ziegler SF.

J Immunol. 2016 Mar 1;196(5):2051-2062. doi: 10.4049/jimmunol.1501491. Epub 2016 Jan 29. Erratum in: J Immunol. 2016 May 1;196(9):3966.

9.

Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients.

Wu M, Assassi S, Salazar GA, Pedroza C, Gorlova OY, Chen WV, Charles J, Taing ML, Liao K, Wigley FM, Hummers LK, Shah AA, Hinchcliff M, Khanna D, Schiopu E, Phillips K, Furst DE, Steen V, Baron M, Hudson M, Zhou X, Pope J, Jones N, Docherty P, Khalidi NA, Robinson D, Simms RW, Silver RM, Frech TM, Fessler BJ, Fritzler MJ, Molitor JA, Segal BM, Movahedian M, Martín J, Varga J, Mayes MD.

Arthritis Res Ther. 2016 Jan 20;18:20. doi: 10.1186/s13075-016-0923-3.

10.

Antinuclear antibody-negative systemic sclerosis.

Salazar GA, Assassi S, Wigley F, Hummers L, Varga J, Hinchcliff M, Khanna D, Schiopu E, Phillips K, Furst DE, Steen V, Baron M, Hudson M, Taillefer SS, Pope J, Jones N, Docherty P, Khalidi NA, Robinson D, Simms RW, Silver RM, Frech TM, Fessler BJ, Molitor JA, Fritzler MJ, Segal BM, Al-Kassab F, Perry M, Yang J, Zamanian S, Reveille JD, Arnett FC, Pedroza C, Mayes MD.

Semin Arthritis Rheum. 2015 Jun;44(6):680-6. doi: 10.1016/j.semarthrit.2014.11.006. Epub 2014 Nov 28.

11.

Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study.

Hsu VM, Chung L, Hummers LK, Wigley F, Simms R, Bolster M, Silver R, Fischer A, Hinchcliff ME, Varga J, Goldberg AZ, Derk CT, Schiopu E, Khanna D, Shapiro LS, Domsic RT, Medsger T, Mayes MD, Furst D, Csuka ME, Molitor JA, Alkassab F, Steen VD.

Semin Arthritis Rheum. 2014 Aug;44(1):55-62. doi: 10.1016/j.semarthrit.2014.03.002. Epub 2014 Mar 5.

PMID:
24709277
12.

Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis.

Mayes MD, Bossini-Castillo L, Gorlova O, Martin JE, Zhou X, Chen WV, Assassi S, Ying J, Tan FK, Arnett FC, Reveille JD, Guerra S, Teruel M, Carmona FD, Gregersen PK, Lee AT, López-Isac E, Ochoa E, Carreira P, Simeón CP, Castellví I, González-Gay MÁ; Spanish Scleroderma Group, Zhernakova A, Padyukov L, Alarcón-Riquelme M, Wijmenga C, Brown M, Beretta L, Riemekasten G, Witte T, Hunzelmann N, Kreuter A, Distler JH, Voskuyl AE, Schuerwegh AJ, Hesselstrand R, Nordin A, Airó P, Lunardi C, Shiels P, van Laar JM, Herrick A, Worthington J, Denton C, Wigley FM, Hummers LK, Varga J, Hinchcliff ME, Baron M, Hudson M, Pope JE, Furst DE, Khanna D, Phillips K, Schiopu E, Segal BM, Molitor JA, Silver RM, Steen VD, Simms RW, Lafyatis RA, Fessler BJ, Frech TM, Alkassab F, Docherty P, Kaminska E, Khalidi N, Jones HN, Markland J, Robinson D, Broen J, Radstake TR, Fonseca C, Koeleman BP, Martin J.

Am J Hum Genet. 2014 Jan 2;94(1):47-61. doi: 10.1016/j.ajhg.2013.12.002.

13.

Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry.

Chung L, Domsic RT, Lingala B, Alkassab F, Bolster M, Csuka ME, Derk C, Fischer A, Frech T, Furst DE, Gomberg-Maitland M, Hinchcliff M, Hsu V, Hummers LK, Khanna D, Medsger TA Jr, Molitor JA, Preston IR, Schiopu E, Shapiro L, Silver R, Simms R, Varga J, Gordon JK, Steen VD.

Arthritis Care Res (Hoboken). 2014 Mar;66(3):489-95. doi: 10.1002/acr.22121.

14.

Can large simple trials help us understand when and how to use generic drugs for uncommon diseases?

Molitor JA, Demets DL.

J Rheumatol. 2013 May;40(5):539-41. doi: 10.3899/jrheum.130314. No abstract available.

PMID:
23637373
15.

Castleman disease and associated autoimmune disease.

Muskardin TW, Peterson BA, Molitor JA.

Curr Opin Rheumatol. 2012 Jan;24(1):76-83. doi: 10.1097/BOR.0b013e32834db525. Review.

PMID:
22157415
16.

Periodontal disease, tooth loss and incident rheumatoid arthritis: results from the First National Health and Nutrition Examination Survey and its epidemiological follow-up study.

Demmer RT, Molitor JA, Jacobs DR Jr, Michalowicz BS.

J Clin Periodontol. 2011 Nov;38(11):998-1006. doi: 10.1111/j.1600-051X.2011.01776.x. Epub 2011 Sep 13.

17.

Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysis.

Sharif R, Fritzler MJ, Mayes MD, Gonzalez EB, McNearney TA, Draeger H, Baron M; Canadian Scleroderma Research Group, Furst DE, Khanna DK, del Junco DJ, Molitor JA, Schiopu E, Phillips K, Seibold JR, Silver RM, Simms RW; GENISOS Study Group, Perry M, Rojo C, Charles J, Zhou X, Agarwal SK, Reveille JD, Assassi S, Arnett FC.

J Rheumatol. 2011 Aug;38(8):1622-30. doi: 10.3899/jrheum.110071. Epub 2011 May 15.

18.
19.

Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial.

Koffeman EC, Genovese M, Amox D, Keogh E, Santana E, Matteson EL, Kavanaugh A, Molitor JA, Schiff MH, Posever JO, Bathon JM, Kivitz AJ, Samodal R, Belardi F, Dennehey C, van den Broek T, van Wijk F, Zhang X, Zieseniss P, Le T, Prakken BA, Cutter GC, Albani S.

Arthritis Rheum. 2009 Nov;60(11):3207-16. doi: 10.1002/art.24916.

20.

Positive selection optimizes the number and function of MHCII-restricted CD4+ T cell clones in the naive polyclonal repertoire.

Chu HH, Moon JJ, Takada K, Pepper M, Molitor JA, Schacker TW, Hogquist KA, Jameson SC, Jenkins MK.

Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):11241-5. doi: 10.1073/pnas.0902015106. Epub 2009 Jun 18.

21.

Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis.

Kim D, Peck A, Santer D, Patole P, Schwartz SM, Molitor JA, Arnett FC, Elkon KB.

Arthritis Rheum. 2008 Jul;58(7):2163-73. doi: 10.1002/art.23486.

22.

Micro magnetic resonance angiography of the finger in systemic sclerosis.

Wang J, Yarnykh VL, Molitor JA, Nash RA, Chu B, Wilson GJ, Fleming J, Schwartz SM, Yuan C.

Rheumatology (Oxford). 2008 Aug;47(8):1239-43. doi: 10.1093/rheumatology/ken215. Epub 2008 Jun 17.

PMID:
18559373
23.

A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease.

Postlethwaite AE, Wong WK, Clements P, Chatterjee S, Fessler BJ, Kang AH, Korn J, Mayes M, Merkel PA, Molitor JA, Moreland L, Rothfield N, Simms RW, Smith EA, Spiera R, Steen V, Warrington K, White B, Wigley F, Furst DE.

Arthritis Rheum. 2008 Jun;58(6):1810-22. doi: 10.1002/art.23501.

24.

Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma.

Duan H, Fleming J, Pritchard DK, Amon LM, Xue J, Arnett HA, Chen G, Breen P, Buckner JH, Molitor JA, Elkon KB, Schwartz SM.

Arthritis Rheum. 2008 May;58(5):1465-74. doi: 10.1002/art.23451.

25.

Capillary regeneration in scleroderma: stem cell therapy reverses phenotype?

Fleming JN, Nash RA, McLeod DO, Fiorentino DF, Shulman HM, Connolly MK, Molitor JA, Henstorf G, Lafyatis R, Pritchard DK, Adams LD, Furst DE, Schwartz SM.

PLoS One. 2008 Jan 16;3(1):e1452. doi: 10.1371/journal.pone.0001452. Erratum in: PLoS ONE. 2008;3(8). doi: 10.1371/annotation/6b021f46-17bd-4ffe-a378-a1b8d24a1398.

26.

Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease.

Gerbino AJ, Goss CH, Molitor JA.

Chest. 2008 Feb;133(2):455-60. Epub 2007 Dec 10.

PMID:
18071023
27.

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study.

Nash RA, McSweeney PA, Crofford LJ, Abidi M, Chen CS, Godwin JD, Gooley TA, Holmberg L, Henstorf G, LeMaistre CF, Mayes MD, McDonagh KT, McLaughlin B, Molitor JA, Nelson JL, Shulman H, Storb R, Viganego F, Wener MH, Seibold JR, Sullivan KM, Furst DE.

Blood. 2007 Aug 15;110(4):1388-96. Epub 2007 Apr 23.

28.

Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis.

Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, Bradley JD, Bingham CO 3rd, Weisman MH, Jackson CG, Lane NE, Cush JJ, Moreland LW, Schumacher HR Jr, Oddis CV, Wolfe F, Molitor JA, Yocum DE, Schnitzer TJ, Furst DE, Sawitzke AD, Shi H, Brandt KD, Moskowitz RW, Williams HJ.

N Engl J Med. 2006 Feb 23;354(8):795-808.

29.
30.

Transcript array analysis in rheumatology.

Molitor JA, Buckner JH, Nepom GT.

Rheum Dis Clin North Am. 2002 Feb;28(1):151-76, vii-viii. Review.

PMID:
11840695
32.
33.

NF-kappa B: a family of inducible and differentially expressed enhancer-binding proteins in human T cells.

Molitor JA, Walker WH, Doerre S, Ballard DW, Greene WC.

Proc Natl Acad Sci U S A. 1990 Dec;87(24):10028-32.

34.

The v-rel oncogene encodes a kappa B enhancer binding protein that inhibits NF-kappa B function.

Ballard DW, Walker WH, Doerre S, Sista P, Molitor JA, Dixon EP, Peffer NJ, Hannink M, Greene WC.

Cell. 1990 Nov 16;63(4):803-14.

PMID:
2225078

Supplemental Content

Loading ...
Support Center